Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with DPP4i nonusers, DPP4i users had a lower risk of ESRD (hazard ratio, 0.81; 95% CI, 0.70-0.94; P=.04) and all-cause mortality (hazard ratio, 0.28; 95% CI, 0.23-0.34; P<.001) after adjustments for CKD, advanced CKD, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.
|
30343892 |
2018 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Numerous studies have found that angiotensin II (Ang II) participates in podocyte apoptosis and exacerbates progression of end-stage kidney disease (ESKD).
|
28676854 |
2017 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that heterozygous substitutions at the AGT M235T and REN A/G(I8-83) loci correlate significantly with ESRD in a north Indian population.
|
25660845 |
2015 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Examination of exome sequencing data in African American T2D-ESKD cases and non-diabetic non-nephropathy controls identified two low-frequency variants in the RREB1 gene, a repressor of the angiotensinogen (AGT) gene previously associated with kidney function, as being associated with T2D-ESKD: rs9379084 (P = 0.00087, OR = 0.26; D1171N) and rs41302867 (P = 0.00078, OR = 0.21; splice site variant).
|
25027322 |
2014 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, there was no a markedly positive association between AGT M235T gene polymorphism and ESRD susceptibility in overall populations, Asians and Africans.
|
23065231 |
2013 |
Chronic kidney disease stage 5
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Some patients with uremia due to ESRD exhibited significantly increased mAb 1G12 binding to blood ACE and increased ACE activity towards angiotensin I accompanied by reduced ACE inhibition by inhibitory mAbs and ACE inhibitors.
|
23166630 |
2012 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discontinuing angiotensin II blockade resulted in recurrent glomerular destabilization, podocyte loss, and progression to ESKD.
|
21937979 |
2012 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, other endogenous substances with genotoxic properties, which are increased in ESRD, could be involved, such as the blood pressure regulating hormones angiotensin II and aldosterone or the inflammatory cytokine TNF-α.
|
22069557 |
2010 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the ACE, AGT, AT1R and CYP gene polymorphisms, only the DD genotype may predispose the individual to increased risk of progression to ESRD in the Chinese population.
|
21163122 |
2010 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study was designed to evaluate the angiotensin-converting enzyme insertion/deletion (ACE-I/D), angiotensinogen (AGT) M235T, and angiotensin II receptor type 1 (ATR1) A1166C and type 2 (ATR2) C3123A gene polymorphisms as risk factors for progression to ESRD in patients with VUR.Methods.
|
19288324 |
2009 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the distribution of angiotensin converting enzyme (ACE), angiotensinogen (AGT) and angiotensin receptor type 1 (ATR1) genetic polymorphisms in children affected by chronic renal failure due to renal hypodysplasia associated with posterior urethral valves or without urethral abnormalities.
|
16006956 |
2005 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, the angiotensinogen -235T allele was found to be related with steroid resistance, renal dysfunction and progression of ESRD in nephrotic syndrome.
|
16525944 |
2005 |
Chronic kidney disease stage 5
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Twelve-lead electrocardiograms (ECGs), serum electrolytes (sodium, potassium, and calcium), and ACE and angiotensin II levels were obtained 10 to 12 hours after a hemodialysis session in 43 patients with ESRD on chronic hemodialysis [mean age (+/-SD), 55 +/- 14 years].
|
16105049 |
2005 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied the angiotensin-converting enzyme (ACE), angiotensinogen (AGT), and angiotensin II type 1 receptor (AT1R) gene polymorphisms for association with susceptibility to primary vesicoureteral reflux (VUR) and disease progression in 74 Taiwanese children, including 16 with end-stage renal disease (ESRD), and 117 normal controls.
|
15045574 |
2004 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Study of the polymorphism of angiotensinogen, anigiotensin-converting enzyme and angiotensin receptor in type II diabetes with end-stage renal disease in Taiwan.
|
12728975 |
2003 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed the effects of the AGT M235T and ATR A1166C polymorphisms on hypertension and age at the end stage renal disease (ESRD).
|
12950120 |
2003 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two hundred and forty-six end-stage renal disease (ESRD) patients on peritoneal dialysis and 183 control subjects, all of Chinese origin, were genotyped for the ACE insertion/deletion (I/D) and the AGT M235T gene polymorphisms.
|
12675870 |
2003 |
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The alpha-adducin (ADD) gene, alone or in combination with the angiotensinogen (AGT) and the angiotensin-converting enzyme (ACE), is a candidate for abnormal blood pressure regulation and thus for increased susceptibility or faster progression to ESRD.
|
11918733 |
2002 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined the A1166C polymorphism at the angiotensin II type 1 (AT1R) locus in patients with end-stage renal disease (ESRD).
|
12187084 |
2002 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The AGT-TT genotype was associated with a faster progression to ESRD in patients with glomerulonephritis (P < 0.05).
|
11422735 |
2001 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. End-Stage Renal Disease Study Group.
|
10916074 |
2000 |
Chronic kidney disease stage 5
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is of note that the presently reported patient did not exhibit any AGT catalytic activity and even so, he progressed towards end-stage renal disease only at 19 years old.
|
10737993 |
2000 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that polymorphisms at the AGT and ACE gene loci are important markers for predicting progression to chronic renal failure in Caucasian patients with IgA nephropathy.
|
9259580 |
1997 |
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was no interaction between age of onset of ESRF and either the angiotensinogen M235T allele or angiotensin 1 receptor A1166C polymorphism.
|
9291178 |
1997 |